Skip to content

Incentives in Diabetic Eye Assessment by Screening

Incentives in Diabetic Eye Assessment by Screening (IDEAS) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02339909
Acronym
IDEAS
Enrollment
1051
Registered
2015-01-16
Start date
2015-03-31
Completion date
2016-07-31
Last updated
2023-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetic Retinopathy

Keywords

Screening, Incentives

Brief summary

This trial is a randomised controlled trial to assess whether annual attendance rates at diabetic eye screening appointments in Kensington, Chelsea and Westminster could be improved by offering invitees a small financial incentive. The research questions are: 1. Are incentives an effective strategy to encourage participation in the screening programme? 2. Does the design of the financial incentive scheme affect its effectiveness in influencing participation in health screening? 3. Does the choice of incentive scheme, if successful, attract patients who have a different demographic or socioeconomic status to those who attend screening regularly? 4. Is offering these incentives a cost-effective strategy for enhancing participation?

Detailed description

An increasing emphasis is being placed on preventative healthcare in the NHS (National Health Service). Screening programmes currently exist in many clinical areas including diabetic retinopathy as well as breast cancer, cervical cancer and cardiovascular disease. In many contexts the benefits of health screening are well documented, but concerns exist about the effectiveness and cost-effectiveness of such programmes as uptake to screening may be very poor in some, generally hard to reach, communities. There are many ways of trying to encourage participation in health promoting activities and it is likely real shifts in behaviour will only come about with a mix of strategies. In this study we set out to see if we can improve screening rates in London, which has both high and low levels of deprivation and specific populations with poor attendance. The ultimate success of a high-quality screening program depends on the uptake rate of the population and novel solutions are required to meet the challenge of achieving this. Diabetes is an increasing public health concern worldwide. There are 2.9 million people diagnosed with diabetes in the UK (United Kingdom) and an estimated 850,000 people who have the condition but are not recognised. Whilst the rates of other vascular risk factors such as hypertension, smoking and hypercholesterolaemia are falling, the rates of diabetes in the UK are rising. This is despite the co-ordinated efforts of primary and secondary care prevention programmes. All patients with diabetes are at risk of developing diabetic retinopathy. This condition is caused by the microscopic damage to small blood vessels to the eye. There is proliferation (growth) of these vessels and these new fragile vessels may bleed and destroy the retina leading to sight loss. It is estimated that in England every year 4,200 people are at risk of blindness caused by diabetic retinopathy and there are 1,280 new cases of blindness caused by diabetic retinopathy. It is the leading cause of sight loss in the UK in the working population and therefore there is a significant social and financial burden associated with the condition. However with timely diagnosis and treatment the risk of blindness can be dramatically reduced. As this condition may well remain silent until catastrophic late manifestations of the disease are evident, the need for an effective screening programme is obvious. The National Screening programme was implemented in England between 2003 and 2006. This involves an annual retinal digital photographic screening offered to all people aged 12 years and older diagnosed with type 1 and type 2 diabetes. The test involves administration of eye drops to the eye and a photograph of the retina taken without contact with the eye. The success of this screening programme is without contest. In 2011-2012, 2,587,000 people in England aged 12 and over were identified with diabetes and over 90% were offered screening for diabetic retinopathy. 1,911,000 received screening which equates to an uptake of 81%. However there is significant variability in uptake in differing areas. Although screening is offered in multiple locations including GP (general practice) surgeries and hospitals, the poor uptake of screening in socially deprived areas is well documented. For example, in Gloucestershire, with each increasing quintile of deprivation, diabetes prevalence increases (odds ratio 0.84), the probability of having been screened for diabetic retinopathy decreases (odds ratio 1.11), and the prevalence of sight-threatening diabetic retinopathy among screened patients increases also (odds ratio of 0.98). Since the effectiveness of any screening programme is intimately linked to the uptake by the population (and in particular uptake by those most at risk), simple, inexpensive and cost effective strategies are required by the NHS to influence population health behaviours in domains where choices are often in sharp contrast to underlying intentions. This has relevance to diabetic retinopathy screening but also more widely as we increasingly try to prevent disease rather than simply treat it. Incentives are central to economics and are used across the public and private sectors to influence behaviour. Psychological phenomena from behavioural economics allow us to design incentive-based interventions that are more effective at delivering improved outcomes. Personal incentives have been used to motivate patients and general populations to change their behaviour. Examples of behaviours targeted include smoking and drug use cessation. Incentives can include cash, vouchers or benefits-in-kind and they can have a profound effect on individual behaviour at a relatively small cost. Interest in offering incentives to foster healthier lifestyles has increased, as the full economic and social costs of bad choices and unhealthy behaviour have become apparent. Incentives have previously been used to improve cancer screening rates, but they have been targeted at the providers of the service rather than people invited to attend for screening. Financial incentives have been seen to be more effective in increasing performance of infrequent behaviours (e.g. vaccinations) rather than in more sustained behaviours (e.g. smoking). As screening usually requires discrete one-off behaviours, incentives may be particularly effective in increasing their uptake. A wider use of incentives in public health interventions is a more recent phenomenon and has attracted controversy and concerns about whether they are effective (and cost effective) or not. This study will provide evidence to policy makers about the role of different incentive schemes in encouraging health promoting behaviours. We do not suggest that providing incentives is the only answer to encouraging screening participation, but if we demonstrate good evidence that they are effective (and cost effective), their targeted application may be indicated. Equally demonstration that incentives of this type are not effective may prevent unnecessary financial loss from the NHS if wider rollout of such programmes is considered.

Interventions

BEHAVIORALFixed financial incentive

Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment.

BEHAVIORALProbabilistic financial incentive

Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment.

BEHAVIORALControl

Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter.

Sponsors

National Health Service, United Kingdom
CollaboratorOTHER_GOV
Imperial College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diabetic patients who were invited to screening in the last 24 months on a yearly basis and failed to attend or contact the screening service to rearrange an appointment

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients Attending Screening AppointmentAt designated appointment date (between three months and one year from previous missed appointment)The participants will be invited to a specific appointment between three months and one year from their previous missed appointment. The primary outcome refers to the number of participants who did attend their appointment.

Secondary

MeasureTime frameDescription
Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.Number of patients with additional management triggered as a result of test at designated screening appointment (between three months and one year)The outcome measure from screening is an ordinal measure indicating whether there is no retinopathy, or varying degrees of retinopathy. This will be measured at the screening appointment (for those participants who attend their appointment). We report whether there is further management required as a result of screening.

Participant flow

Pre-assignment details

Due to the nature of the study, informed consent could not be collected. The number of participants Started in the Participant Flow (1274) refers to the number randomised. Following randomisation, but prior to being sent the intervention letter, 223 participants became ineligible, so 1051 participants were actually enrolled in the study.

Participants by arm

ArmCount
Control
The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.) Control: Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter.
435
Fixed Incentive
The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.) Fixed financial incentive: Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment.
312
Probabilistic Incentive
The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.) Probabilistic financial incentive: Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment.
304
Total1,051

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyBecame ineligible after randomisation896371

Baseline characteristics

CharacteristicControlFixed IncentiveProbabilistic IncentiveTotal
Age, Customized
16-65 years
229 Participants173 Participants176 Participants578 Participants
Age, Customized
Over 65 years
206 Participants139 Participants128 Participants473 Participants
Region of Enrollment
United Kingdom
435 participants312 participants304 participants1051 participants
Sex: Female, Male
Female
172 Participants142 Participants128 Participants442 Participants
Sex: Female, Male
Male
263 Participants170 Participants176 Participants609 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 4351 / 3120 / 304
serious
Total, serious adverse events
0 / 4350 / 3120 / 304

Outcome results

Primary

Number of Patients Attending Screening Appointment

The participants will be invited to a specific appointment between three months and one year from their previous missed appointment. The primary outcome refers to the number of participants who did attend their appointment.

Time frame: At designated appointment date (between three months and one year from previous missed appointment)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
ControlNumber of Patients Attending Screening Appointment34 Participants
Fixed IncentiveNumber of Patients Attending Screening Appointment17 Participants
Probabilistic IncentiveNumber of Patients Attending Screening Appointment10 Participants
Secondary

Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.

The outcome measure from screening is an ordinal measure indicating whether there is no retinopathy, or varying degrees of retinopathy. This will be measured at the screening appointment (for those participants who attend their appointment). We report whether there is further management required as a result of screening.

Time frame: Number of patients with additional management triggered as a result of test at designated screening appointment (between three months and one year)

Population: These are the numbers of each group that attended screening and had retinopathy screening

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
ControlNumber of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.6 Participants
Fixed IncentiveNumber of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.7 Participants
Probabilistic IncentiveNumber of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.5 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026